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Abstract
Ceramides are known to promote insulin resistance in a number of metabolically important tissues including skeletal
muscle, the predominant site of insulin-stimulated glucose disposal. Depending on cell type, these lipid intermediates have
been shown to inhibit protein kinase B (PKB/Akt), a key mediator of the metabolic actions of insulin, via two distinct
pathways: one involving the action of atypical protein kinase C (aPKC) isoforms, and the second dependent on protein
phosphatase-2A (PP2A). The main aim of this study was to explore the mechanisms by which ceramide inhibits PKB/Akt in
three different skeletal muscle-derived cell culture models; rat L6 myotubes, mouse C2C12 myotubes and primary human
skeletal muscle cells. Our findings indicate that the mechanism by which ceramide acts to repress PKB/Akt is related to the
myocellular abundance of caveolin-enriched domains (CEM) present at the plasma membrane. Here, we show that
ceramide-enriched-CEMs are markedly more abundant in L6 myotubes compared to C2C12 myotubes, consistent with their
previously reported role in coordinating aPKC-directed repression of PKB/Akt in L6 muscle cells. In contrast, a PP2A-
dependent pathway predominantly mediates ceramide-induced inhibition of PKB/Akt in C2C12 myotubes. In addition, we
demonstrate for the first time that ceramide engages an aPKC-dependent pathway to suppress insulin-induced PKB/Akt
activation in palmitate-treated cultured human muscle cells as well as in muscle cells from diabetic patients. Collectively,
this work identifies key mechanistic differences, which may be linked to variations in plasma membrane composition,
underlying the insulin-desensitising effects of ceramide in different skeletal muscle cell models that are extensively used in
signal transduction and metabolic studies.
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Introduction
Once bound to its receptor, insulin stimulates a signalling
network that functions to regulate whole-body glucose homeostasis
by coordinating numerous physiological processes. Defects in the
activation of insulin-induced signalling cascades are often associ-
ated with insulin resistance, a characteristic feature of obesity and
type 2 diabetes [1]. The mechanisms by which insulin resistance
develops are not yet fully understood but recent work has shown
that forcing cells to accumulate fatty acids beyond their storage
capacity may lead to insulin desensitisation through the generation
of toxic lipid intermediates such as ceramide [2,3].
Skeletal muscle is the major tissue responsible for insulin-
stimulated glucose disposal and therefore considered as a primary
target in the onset of insulin resistance. Various studies have
suggested that ectopic accumulation of ceramide in response to
oversupply of saturated fatty acids including palmitate may
underlie the development of insulin resistance in this tissue [4–6].
Indeed, we and others have demonstrated that ceramide can
impair insulin action through inhibition of protein kinase B (PKB/
Akt), a key signal transduction intermediate that plays a pivotal
role in coordinating the insulin-dependent uptake and utilization
of glucose [7,8]. Two skeletal muscle cell lines that have been
extensively used to study the deleterious effects of ceramide upon
insulin action are rat L6 and mouse C2C12 muscle cells. In
differentiated rat L6 myotubes, treatment with palmitate or
exogenous ceramide leads to the activation of the atypical protein
kinase C isoform PKCf which in turn directly interacts with and
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phosphorylates the pleckstrin homolog (PH) domain of PKB/Akt
at Thr34. As a result of this interaction, PKB/Akt becomes
sequestered into specialized domains of the plasma membrane
known as caveolin-enriched microdomains (CEM) thereby pre-
venting its recruitment to PIP3-enriched regions where it is
normally activated in response to insulin [9–11]. In contrast, whilst
exposure of C2C12 myotubes to palmitate has also been shown to
result in the activation of aPKCf, PKB/Akt becomes repressed
primarily through its dephosphorylation by protein phosphatase
2A (PP2A) [12].
In this study, we set out to explore this differential mode of
inhibition by ceramide upon insulin signalling in L6 and C2C12
myotubes. Importantly, we previously reported that in cells which
lack CEM (e.g. fibroblasts), ceramide does not inhibit PKB/Akt
through the ‘‘PKCf-CEM’’ pathway, but rather through activa-
tion of PP2A [11]. This is in contrast to cells with abundant CEM
(e.g. 3T3-L1 adipocytes) wherein ceramide acts to repress PKB/
Akt via the PKCf-CEM pathway [11]. We therefore hypothesised
that variations in CEM content between these different muscle cell
lines may account for the distinct signalling pathways utilised by
ceramide to impair insulin action. Herein, we demonstrate that
whilst ceramide impairs insulin-stimulated PKB/Akt activation via
the ‘PKCf-CEM’ pathway in L6 myotubes, this same lipid
intermediate does so via a PP2A-dependent mechanism in C2C12
myotubes which exhibit a lower CEM content relative to L6
myotubes.
In addition, little is known about the functional mechanism(s)
responsible for conveying the insulin desensitising effects of
ceramide in human skeletal muscle. Therefore, we explored the
potential involvement of the ‘PKCf-CEM’ and PP2A pathways in
primary cultured human muscle cells, which represent a good
model for studying human skeletal muscle function [13] and can
be modulated ex vivo [13]. We show that similar to L6 myotubes,
it is the ‘‘PKCf-CEM’’ pathway which predominantly mediates
the repressive effects of ceramide upon PKB/Akt in human muscle
cells.
Methods
Materials
All reagent-grade chemicals, insulin, palmitate, and BSA were
purchased from Sigma-Aldrich. C2-ceramide was obtained from
Cayman Chemical Company. Complete protein phosphatase
inhibitor tablets were obtained from Boehringer-Roche Diagnos-
tics. Antibodies against native PKB/Akt, Ser473-PKB/Akt and 21/
9Ser GSK3a/b were from Cell Signalling (New England Biolabs),
caveolin-3, PKCf, PP2A and hemagglutinin from Santa Cruz
Biotechnology and b-actin from Sigma-Aldrich. Horseradish
peroxidase anti-rabbit, -mouse and -sheep/goat IgGs were from
Jackson ImmunoResearch Laboratories and the enhanced chemi-
luminescent substrate was from Pierce-Perbio Biotechnology.
Cell culture
L6 muscle cells were grown as a monolayer as described
previously [14] to the stage of myotubes in a-minimum essential
medium containing 2% fetal calf serum and 1% antimicotic/
antibiotic solution. C2C12 myoblasts were maintained in Dulbec-
co’s modified Eagle’s medium (Gibco) containing 10%(v/v) fetal
bovine serum. For differentiation into myotubes, the myoblasts
were grown to confluence and the media were replaced with
DMEM containing 2% horse serum. Both cell lines were
maintained at 37uC in a humidified atmosphere of 5% CO2,
95% air. Myotubes were used for experiments 4 days following
differentiation.
Human skeletal muscle cells
Biopsies from healthy adult lean volunteers were obtained in the
context of approved preclinical and clinical trials [15], and via the
Tissue Bank for Research (Myobank) of the French Association
against Myopathies (AFM), in agreement with the French
bioethical law (law no 94–654 of 29 July 1994, modified 22
January 2002) on informed consent. Muscle samples from three
adult type 2 diabetic patients were obtained from healthy tissue
after leg amputation. Donors had no clinical signs of muscular
disease and sampled tissues had no bacterial contamination. No
clinical and biological infection has been observed (ultra-sensitive
C reactive protein at 6.6+/22.6 mg/L). At baseline, HbA1c and
fasting glycaemia of type 2 diabetic patients were respectively
7.9+/20.31% and 7.59+/20.44 mmoles/L. Fresh muscle sam-
ples were minced and enzymatically dissociated with collagenase.
Myoblasts were purified, grown and differentiated as myotubes as
previously described [16].
Preparation of whole cell lysates
Cells were lysed following experimental manipulation (see figure
legends) in an appropriate volume of lysis buffer [14].
Preparation of detergent-resistant membranes (DRM)
DRM were prepared as described previously [10]. Cells were
homogenized into 25 mM MES (2-[N-Morpholino]ethanesulfonic
acid), pH 6.0, 150 mM NaCl, 1% (w/v) Triton X-100, complete
inhibitor tablet and lysate ran on a sucrose gradient. The gradient
was centrifuged at 120,000 g for 20 h at 4uC. DRM fractions were
then collected and frozen at 220uC until required.
DRM-containing ceramide quantification
700 mL of each DRM fraction were freeze-dried and subse-
quently extracted once with chloroform/methanol (C/M) (2:1),
once with C/M (1:1) and once with C/M (1:2). The combined C/
M extracts were freeze dried and solubilized in 2 mL of C/M (1:1)
with 3M of potassium hydroxide. The solution is incubated
overnight at 50uC. 800 mL of distilled water (W) is added. The
solution is neutralized using hydrochloric acid 1N. Organic extract
was washed twice with C/M/W (3:48:47), dried under nitrogen
and dissolved in 50 mL of C/M (1:1) before analysis. High
Performance Thin Layer Chromatography (HPTLC) analyses
were performed with a multistep development. A first develop-
ment was realized with the solvent system Hexane/diethyl ether/
acetic acid (30:15:0.5) until a developing distance of 80 mm (from
the lower edge of the plate). The second and third development
was realized with the solvent system C/M/W (40:10:1) until the
respective developing distance of 30 mm and 50 mm. The fourth
development was realized with the solvent system C/M/acetic
acid (47:2:0.5) until a developing distance of 80 mm. And the last
development was realized with the solvent system Hexane/diethyl
ether/acetic acid (30:15:0.5) until a developing distance of 80 mm.
After each development the plate was dried 5 minutes. Bands were
detected after immersion in a charring solution and drying at
250uC during 1 minute. Quantification was realized by densitom-
etry with CAMAG TLC scanner 4 and winCATS software in
absorption mode at 560 nm using a tungsten lamp.
Analysis of sphingolipid content
Sphingolipids were extracted an assessed as described previously
[17].
Ceramide Action in Muscle Cells
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Glucose transport
Human myotubes were washed rapidly with HEPES-buffered
saline (HBS; 20 mM HEPES-Na (pH 7.4), 140 mM NaCl,
2.5 mM MgSO4, 5 mM KCl, 1 mM CaCl2), and glucose uptake
was assayed by incubating cells with 10 mM 2-deoxy-[3H]-D-
glucose (1 mCi/ml, 26.2 Ci/mmol) for 15 min in HBS. Carrier-
mediated uptake was determined by quantitating cell-associated
radioactivity in the presence of 10 mM cytochalasin B (an
inhibitor of facilitative glucose transport). Radioactive medium
was aspirated rapidly followed by three cell washes in ice-cold
isotonic saline solution (0.9% NaCl, w/v) prior to lysis in 0.05 M
NaOH [18]. Cell-associated radioactivity was determined by
liquid scintillation counting and protein determined by the method
of Bradford [19].
Immunoblotting
Cell lysates were subjected to SDS/PAGE and immunoblotted
as previously reported [14]. Nitrocellulose membranes were
probed with various antibodies as described in the figure legends.
Detection of primary antibodies were performed using appropriate
peroxidase-conjugated IgGs and protein signals were visualized
using enhanced chemiluminescence (Thermo Scientific Pierce) by
exposure to Kodak autoradiographic film.
Statistical analysis
Statistical analysis was carried out using a Student’s t test. Data
were considered statistically significant at p values ,0.05 and
notified by *.
Results
In an initial attempt to identify factors underpinning the distinct
mechanisms involved in mediating the repressive effects of
ceramide upon PKB/Akt in L6 and C2C12 myotubes through
PKCf and PP2A respectively, we hypothesised that differences in
CEM abundance and/or composition may account for these
differential modes of action. This was based on our previous
published work demonstrating the key role that CEM abundance
plays in determining ceramide-induced pathways leading to PKB/
Akt inhibition in non-muscle cell types [11]. We selected caveolin-
3 as a CEM marker since this protein is the predominant caveolin
isoform expressed in muscle cells and is known to play a crucial
role in maintaining CEM structure [20]. Immunoblot analysis of
caveolin-3 revealed no significant difference in total caveolin-3
protein content in whole cell lysates of fully differentiated L6 and
C2C12 muscle cells (around 3 ng caveolin-3 per mg total protein
lysate), as shown in figure 1A. We next examined caveolin-3
protein abundance in CEM structures by isolating detergent
resistant membranes (DRM) on discontinuous sucrose density
gradients [10], and immunoblotting the resulting DRM fractions
for caveolin-3. Interestingly, Figure 1B shows that caveolin-3
protein expression in DRM (fractions 3 to 5) obtained from L6
myotubes was approximately 3-fold greater compared to those
isolated from C2C12 myotubes. This suggests higher CEM
abundance in L6 versus C2C12 plasma membranes. Because
ceramide is known to accumulate within CEMs [21], we assessed
whether ceramide concentration would correlate with CEM
caveolin-3 content in DRM fractions isolated from these two
muscle cell lines. To investigate this, we treated L6 and C2C12
myotubes with 100 mM short-chain C2-ceramide for two hours
prior to isolation of DRM fractions that were subsequently used
for quantitative determination of ceramide content. Figure 1 C
shows that ceramide accumulates in DRM fractions 3 to 6 of both
cell lines but to a far lesser extent (10 times less in terms of
abundance) in C2C12 compared to L6 myotubes. Therefore,
lower CEM abundance in C2C12 myotubes may account for the
reduced capacity of these cells to retain ceramide in active
membrane microdomains. This may also help to explain why
inhibition of PKB/Akt by ceramide occurs outside these mem-
brane domains and is mainly dependent upon PP2A activation in
C2C12 myotubes [8–10].
To test this possibility, we examined whether the ‘‘PKCf-
CEM’’ pathway which inhibits PKB/Akt in L6 myotubes may also
be functional in C2C12 myotubes. As predicted based on
comparative CEM analysis, whilst C2-ceramide promotes the
recruitment of PKCf into L6 CEM domains, no PKCf was
detected in CEMs (fractions 3–5) isolated from C2C12 myotubes
challenged with C2-ceramide (figure 2A). Furthermore, PP2A was
not detected in ceramide-treated CEM from either muscle cell
lines (figure 2A) in accordance with previous work showing that
ceramide-activated PP2A acts outside the CEM environment [11].
Having established that PKCf is not recruited to CEM in
response to ceramide in C2C12 myotubes, we next assessed
whether the presence of CEM was dispensable for ceramide to
repress PKB/Akt in these cells. Figure 2B shows that in L6
myotubes, ceramide-mediated inhibition of PKB/AktSer473
phosphorylation in response to insulin was prevented by methyl
b-cyclodextrin (MbCD), a cholesterol depleting agent that has
been shown to disrupt CEM integrity without affecting insulin
signalling capacity [10]. This demonstrates the importance of
CEM in supporting ceramide action in these cells. Moreover, we
used either okadaic acid (OKA), a potent inhibitor of protein
phosphatase 2A (PP2A), and the pharmacological Protein Kinase
C (PKC) inhibitor Ro 31.8220 to determine which ceramide-
activated pathway (aPKCf or PP2A) mediates the repressive effect
of ceramide on PKB/Akt. The bisindolemaleimide Ro 31.8220
potently inhibits conventional and novel PKCs in an ATP-
competitive manner with IC50 values in the submicromolar range,
as well as atypical PKCs in the micromolar range [9]. Figure 2C
shows that whilst applying OKA (500 nM) displays no significant
effect, Ro 31.8220 (at 5 mM, optimal final concentration to
counteract the activation of aPKCf by ceramide in L6 myotubes,
figure S1A) is able to largely prevent the negative action of
ceramide upon the insulin-induced phosphorylation of PKB/Akt,
thereby confirming the importance of the ‘‘CEM- PKCf’’
pathway in mediating this insulin desensitising effect in L6
myotubes.
In contrast, in C2C12 myotubes, treatment with MbCD did not
prevent the repressive action of either palmitate (ceramide
precursor) or C2-ceramide upon insulin-stimulated PKB/Akt
Ser473 phosphorylation, or upon phosphorylation of one of its
physiological downstream targets, GSK3a/b (figure 2D). The lack
of CEM involvement in ceramide action in C2C12 myotubes was
further confirmed by overexpressing an inactive dominant
negative PKCf mutant (KD- PKCf) in these cells. Figure 2D
shows that, in contrast to what has previously been reported in L6
myotubes [9], prevention of PKCf activation does not counteract
either palmitate nor ceramide mediated repression of insulin-
induced PKB/Akt and GSK3a/b phosphorylation. Furthermore,
inhibition of PP2A using OKA (at 500nM, optimal final
concentration to counteract the activation of PP2A by ceramide
in C2C12 myotubes, figure S1B) was found to completely prevent
palmitate and ceramide mediated suppression of PKB/Akt and
GSK3a/b phosphorylation in insulin treated C2C12 myotubes
(figure 2D). Together, these observations suggest that, depending
on cellular CEM abundance, fatty acid overload can inhibit insulin
induced PKB signalling through at least one of two distinct
mechanisms.
Ceramide Action in Muscle Cells
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We next explored which of these mechanisms is likely to
predominate in human muscle cells.
To investigate this, we used primary cultures of muscle cells
derived from human biopsies. These cells have been shown to
differentiate into myotubes in culture and are insulin responsive
[16]. First, we wanted to establish whether our primary human
muscle cells responded to palmitate treatment through assessing
their ability to generate ceramide. Figure 3A shows that incubation
of cultured human myotubes with 0.75 mM palmitate for 24 h led
to significant increases in the cellular content of three distinct
ceramide species (i.e. C16-, C18-, and C20 ceramides). Impor-
tantly, the ability of palmitate to promote these elevations in
intracellular ceramide was attenuated in the presence of myriocin,
a pharmacological inhibitor of the enzyme serine palmitoyl
transferase (SPT) which catalyses the initial rate limiting step of
de novo ceramide synthesis [22].
Subsequently, we assessed whether endogenous ceramide
production from palmitate would impair insulin action in human
muscle cells. Figure 3B shows that prolonged (24 h) incubation of
human myotubes with palmitate completely abrogated insulin-
induced PKB/Akt Ser473 phosphorylation. However, when
human myotubes were pre-incubated with myriocin, the insulin
desensitising effect of palmitate was completely prevented, thereby
highlighting the important role that ceramide accumulation plays
in mediating palmitate induced insulin resistance in human muscle
cells (figure 3B).
Next, we explored the mechanism by which ceramide inhibits
insulin signalling in human muscle cells. To do this, we treated
human myotubes with C2-ceramide for 2 h prior isolating CEM
domains. As observed in L6 myotubes (figure 2A), C2-ceramide
treatment induced recruitment of PKCf into CEM domains of
human myotubes (figure 4A). Then, to determine whether the
ceramide-activated PKCf pathway was involved in repressing
PKB/Akt activity in human muscle cells, we suppressed ceramide
induced activation of PKCf using either Ro 31.8220 (5 mM), or by
overexpressing the inactive kinase-dead (KD)-PKCf mutant in
Figure 1. Levels of caveolin expression and ceramide content in both L6 and C2C12 myotubes. A. 15 mg of L6 and C2C12 lysates were
immunoblotted alongside 65 ng and 130 ng of recombinant caveolin-3-GST (cav-3-GST) protein with an antibody against caveolin-3 (left panel).
Bands were quantified and compared to known quantities of recombinant cav-3 proteins. Results were expressed as ng of cav-3 protein per mg of L6
or C2C12 protein lysat (right panel). B. L6 and C2C12 myotubes were solubilized in 1% Triton X-100 at 4uC and fractionated on sucrose gradients to
isolate detergent resistant membranes (DRM) as described in the Methods section. Resulting fractions were collected from top to bottom of the
gradient. Equal amounts of protein (1 mg) from fractions 2 to 8 of the sucrose gradient were then immunoblotted using an anti-caveolin-3 antibody.
Bands were quantified and caveolin-3 content in L6 cells was expressed as fold increase relative to caveolin-3 content in C2C12 cells. * Significant
change p,0.05 relative to C2C12 cells. These are representative of at least three independent experiments. C. Total ceramide content was quantified
in DRM-containing fractions (3–8 of the sucrose gradient) from both L6 and C2C12 myotubes. These are representative of three independent
experiments.
doi:10.1371/journal.pone.0101865.g001
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these cells. Figure 4B shows that application of Ro 31.8220 or
expression of the KD- PKCf mutant were able to prevent the
ability of palmitate to reduce insulin-stimulated phosphorylation of
PKB/Akt in human cells. In contrast, the PP2A inhibitor okadaic
acid did not counteract the repressive action of palmitate towards
PKB/Akt (figure 4B). In accordance with its ability to induce
PKB/Akt activation, insulin stimulated glucose uptake by over 2-
fold in control human myotubes (figure 4C). Importantly, whilst
palmitate provision led to a profound reduction in insulin-induced
glucose transport, this inhibition was completely prevented in
human muscle cells cotreated with Ro 31.8220 (figure 4C). These
findings indicate that, in human muscle cells, ceramide acts to
impair PKB/Akt predominantly through activation of the PKCf
pathway.
Several studies have previously demonstrated that myotubes
derived from type 2 diabetic patients conserve important
characteristics of the diabetic phenotype [23–25]. For example,
insulin stimulated PKB/Akt phosphorylation in cultured human
diabetic myotubes is reduced compared to that observed in non-
diabetic human myotubes (figure 5A). Interestingly, pre-incubation
with Ro 31.8220, but not OKA, markedly improved insulin
responsiveness in diabetic myotubes (figure 5B). In contrast,
neither Ro 31.8220 nor OKA significantly altered insulin
stimulated PKB/Akt phosphorylation in human control myotubes
(figure 5C).
Collectively these observations indicate that it is the PKCf
pathway which prevails in conveying the inhibition of PKB/Akt
signalling by excess of lipids in the context of type 2 diabetes.
Discussion
The findings presented in the current study indicate that the
inhibitory effects of ceramide on insulin-induced PKB/Akt
signalling can be mediated through two distinct mechanisms
Figure 2. Mechanism of ceramide action on the insulin signalling pathway in both L6 and C2C12 myotubes. A. L6 and C2C12 myotubes
were treated with 100 mM C2-ceramide for 2 h before isolation of DRMs. Equal amounts of protein (1 mg) of each fraction were then immunoblotted
for the presence of PKCf, PP2A and caveolin-3. These are representative immunoblots from three independent experiments. B. L6 myotubes were
pre-incubated with 100 mM C2-ceramide for 2 h and with 5 mM MbCD for the last 30 min. Cells were then stimulated with 100 nM insulin for 10 min
before being lysed and immunoblotted using either a phospho-specific antibody directed against Ser473PKB/Akt or a pan PKB antibody. C. Control
C2C12 myotubes or KD-PKCf-infected C2C12 myotubes were incubated with 100 mM C2-ceramide for 2 h or with 0.75 mM palmitate for 16 h.
Control C2C12 myotubes were then treated with 500 nM okadaic acid (OKA) or with 5 mM MbCD the last 30 min. All cells were treated with 100 nM
insulin for the last 10 min before being lysed. Cell lysates were immunoblotted with antibodies against native PKB/Akt, Ser473PKB/Akt, Ser21/9GSK3 a/
b, b-actin and hemagglutinin (HA). Scanning densitometry was performed to quantify changes in Ser473PKB/Akt abundance in cell lysates. Bars
represent mean +/2 SEM. * Significant change p,0.05 relative to the untreated control. Blots shown represent at least three separate experiments.
doi:10.1371/journal.pone.0101865.g002
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depending on muscle cell type. In rat L6 myotubes, ceramide acts
by promoting the activation of PKCf and its subsequent
recruitment to plasma membrane CEMs. In contrast, in mouse
C2C12 myotubes, ceramide represses PKB/Akt activity through
stimulation of cytoplasmic phosphatase PP2A. Importantly, we
show that differences in CEM abundance may be an important
factor in determining which mechanism is prominent within any
particular cell type.
One possible explanation for the observed differences in CEM
abundance and distinct modes of ceramide action in these two
muscle cell lines, may be partly due to their contrasting abilities to
differentiate from myoblasts into mature myotubes. Both L6 and
C2C12 myoblasts exhibit characteristic features of muscle
myogenesis, including migration and proliferation in medium
containing 10% (v/v) foetal calf serum, followed by elongation and
fusion to form myotubes following serum reduction. Interestingly,
previous studies have shown that L6 cells differentiate readily into
myotubes when maintained in medium containing 2% (v/v)
serum, whereas C2C12 differentiation is more pronounced in
serum-free medium compared to a serum-containing system
[26,27]. Thus, under standard conditions used to differentiate
both cell lines (i.e. 2% (w/w) serum), it is possible that L6
myotubes mature more rapidly and/or more efficiently than
C2C12 myotubes. However, since caveolins are late differentiation
markers [28] and we see similar levels of caveolin-3 content in
both differentiated cell types (figure 1A), this is unlikely to account
for any mechanistic differences, and rather suggest that these two
muscle cell models display different membrane characteristics,
reinforcing the importance of our study.
Another key finding from this work concerns the identification
of the process by which ceramide mediates insulin desensitisation
in human muscle cells. To investigate this, we utilised human
muscle satellite cells obtained from either insulin sensitive or
diabetic donors that we differentiated in vitro into mature
myotubes. There are several advantages using this cell model,
including its morphological, biochemical and metabolic similarity
to adult skeletal muscle cells [13]. Importantly, these cultured
myotubes have been shown to maintain metabolic properties of
the donor [13]. Similar to what we observed in L6 and C2C12
myotubes, we found that treatment of cultured insulin sensitive
human myotubes with palmitate led to both an increase in the
biosynthesis of three ceramide species (C16-, C18- and C20-
ceramides) and an associated reduction in insulin stimulated PKB/
Akt activation. Interestingly, the levels of similar ceramide species
Figure 3. Effect of Palmitate on ceramide production and insulin sensitivity in human muscle cells. Human myotubes were incubated
with 0.75 mM palmitate for 48 h in the presence or absence of 10 mM myriocin. A. Following this incubation, muscle cells were harvested in ice-cold
PBS and lipids extracted to assess ceramide species content as described in the Methods section. Bars represent mean 6 SEM from 3 separate
experiments and * denote a significant difference from the untreated control values (P,0.05). B. Cells were then stimulated with 100 nM insulin for
the last 10 min before being lysed and immunoblotted using either a phospho-specific antibody directed against Ser473PKB/Akt or a pan PKB
antibody.
doi:10.1371/journal.pone.0101865.g003
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(C16- and C18-ceramides) have also previously been reported to
be increased in myotubes obtained from type 2 diabetic individuals
compared to controls [6]. Therefore, these observations suggest
that these specific ceramide species may play a key role in
mediating the deleterious effects of palmitate upon insulin signal
transduction. In accordance with this, we demonstrate that
inhibition of endogenous ceramide production with myriocin
abolishes palmitate-induced insulin resistance in our human
myotubes. Furthermore, in line with our observations in L6
muscle cells [8,9], palmitate-derived ceramide acts to inhibit
insulin signalling through activation of the ‘‘PKCf-CEM’’
pathway in human myotubes. Importantly, we confirmed this by
using human myotubes that have been made insulin resistant
through palmitate exposure, as well as using primary culture of
skeletal muscle cells from diabetic patients. It is important to note
that the latter cell model has been extensively studied and displays
several metabolic defects that characterize in vivo insulin resis-
tance of skeletal muscle such as inhibition of insulin stimulated
glucose uptake and glycogen synthesis [24,25,29,30], concomitant
with impaired insulin signalling [23,31].
Together, these data implicate the ‘‘PKCf-CEM’’ pathway as
an important therapeutic target to counteract the deleterious
effects of saturated fatty acids and their derived lipid intermediates
upon insulin signalling in muscle cells. It is important to emphasise
that myotubes derived from human subjects used in the present
study could present altered membrane structure, gene expression
and function due to in vitro culture and differentiation. Therefore,
it would be interesting to confirm our results in intact muscle.
In summary, our study highlights key mechanistic differences by
which ceramide can impair insulin action in rat L6 and mouse
C2C12 myotubes. Importantly, our findings suggest that the
effectiveness of distinct ceramide-induced pathways to promote
insulin resistance in these cell lines, namely through activation of
atypical PKC isoforms and PP2A respectively, may be determined
by cellular CEM abundance and/or composition. Furthermore,
we demonstrate for the first time that ceramide acts to repress
Figure 4. Ceramide action on the insulin signalling pathway in human myotubes. A. Human myotubes were treated with 100 mM C2-
ceramide for 2 h before isolation of DRMs. Equal amounts of protein (1 mg) of each fraction were then immunoblotted for the presence of PKCf and
caveolin-3. These are representative immunoblots from three independent experiments. B. Human myotubes from control donors were treated with
0.75 mM palmitate for 48 h in the presence or absence of Ro 31.8220 (5 mM, 48 h) or OKA (500 nM, last 30 min). KD-PKCf-infected human myotubes
were treated with 0.75 mM palmitate for 48 h. Cells were then stimulated with 100 nM insulin for the last 10 min before being lysed. Cell lysates were
immunoblotted with antibodies against Ser473PKB/Akt, b-actin and hemagglutinin (HA). Scanning densitometry was performed to quantify changes
in Ser473PKB/Akt abundance in cell lysates. Bars represent mean +/2 SEM. * denotes significant change p,0.05 relative to the untreated control. Blots
shown represent at least three separate experiments. C. Human myotubes were incubated with 0.75 mM palmitate for 48 h in the presence or
absence of Ro 31.8220. Cells were then treated with 100 nM insulin for the last 30 min prior to the measurement of 2-deoxy-glucose uptake as
described in the experimental section. Bars represent mean +/2 SEM. * Significant change p,0.05 relative to the untreated control (n = 3).
doi:10.1371/journal.pone.0101865.g004
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insulin-induced PKB/Akt signalling in primary human myotubes
through a pathway dependent on PKCf. Together, these data
raise awareness of the key role that cell membrane structure and/
or composition may play in determining the effectiveness and/or
predominance of those pathways which can potentially cause
insulin resistance in different skeletal muscle cell models.
Furthermore, our findings emphasise the need for caution when
interpreting and comparing data from different muscle cell lines,
particularly when exploring the role of fatty acid derived lipids
such as ceramide in the modulation of insulin-regulated signalling
and its associated processes.
Supporting Information
Figure S1 A: L6 myotubes treated with or without
100 mM C2-ceramide in the presence of different
concentrations of Ro 31–8220 for 2 h, prior to stimula-
tion with insulin (100 nM for 10 min). B: C2C12 myotubes
treated with or without 100 mM C2-ceramide for 2 h in the
presence of different concentrations of OKA for the last 30 min,
prior to stimulation with insulin (100 nM for 10 min).
(TIF)
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